Biogen (MEX:BIIB) Cash-to-Debt

: 0.74 (As of Dec. 2022)

View and export this data going back to 2013. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biogen's cash to debt ratio for the quarter that ended in Dec. 2022 was 0.74.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biogen couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.

The historical rank and industry rank for Biogen's Cash-to-Debt or its related term are showing as below:

MEX:BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25 Med: 4.83 Max: No Debt
Current: 0.74

During the past 13 years, Biogen's highest Cash to Debt Ratio was No Debt. The lowest was 0.25. And the median was 4.83.

MEX:BIIB's Cash-to-Debt is ranked worse than
53.81% of 1089 companies
in the Drug Manufacturers industry
Industry Median: 0.92 vs MEX:BIIB: 0.74

Biogen Cash-to-Debt Historical Data

The historical data trend for Biogen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.60

0.70

0.33

0.50

0.74

Biogen Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Cash-to-Debt																0.50	0.49	0.64	0.74	0.74

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biogen's Cash-to-Debt falls in comparison to its industry or sector. The grey bar indicates the Cash-to-Debt's extreme value range as defined by GuruFocus.

Biogen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biogen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	95971.293473429	/	(0	+	129732.28724519)
	=	0.74

Biogen's Cash to Debt Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	95971.293473429	/	(0	+	129732.28724519)
	=	0.74

Biogen (MEX:BIIB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biogen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.